



Stefan Jungbluth, PhD MBA European Vaccine Initiative (EVI)

TRANSVAC – Supporting vaccines of the future





TRANSVAC – An overview





TRANSVAC – An overview



Supporting innovation and development of **human** and **veterinary**, **prophylactic** and **therapeutic** vaccines



Accelerating vaccine development by developing & applying cutting-edge technologies



Offering training courses to provide fundamental and advanced knowledge in vaccinology



Developing a sustainable vaccine infrastructure accelerating vaccine R&D



TRANSVAC – An overview



Supporting innovation and development of human and veterinary, prophylactic and therapeutic vaccines



Accelerating vaccine development by developing & applying cutting-edge technologies



Offering training courses to provide fundamental and advanced knowledge in vaccinology



Developing a sustainable vaccine infrastructure accelerating vaccine R&D



Additional EC funding specifically for supporting development of COVID-19 vaccines!



TRANSVAC and COVID-19

Project	Title	Institution		Country	Gender	Service providers
MUCOVAC	Development of a vaccine candidate against SARS-COV-2 via the muNS-Mi platform by production of microspheres (MS) containing three different viral antigens	Rinlogical Chamistry	Research Institution	ES	М	BPRC, NL/HZI, DE/ EATRIS, NL
P-nCoV-Gap	Gaps in the project: Prevention of SARS-CoV-2 infection in at risk groups through development and clinical testing of a novel Virus Like Particle (VLP) vaccine.	' '	Research Institution	DK	M	SSI, DK/HZI, DE/UNISI, IT/ BPRC, NL/ EATRIS,
SPORCOVAX	Novel mucosal vaccination to covid-19 and influenza with both prophylactic and therapeutic potential	SporeGen Ltd.	SME	UK	М	HZI, DE/IRTA, SP
COROVAC-LITE	Immunogenicity of recombinant SARS-CoV-2 Spike Protein Subunits plus a novel, potent adjuvant in Non- Rodent Species; Possibilities of a Single-Low-Dose Vaccine against Coronavirus	LiteVax BV / ImmunoPrecise Antibodies Europe (IPA)	SME	NL	М	IRTA, ES
OVX-COVID	DEMOnstrate the efficacy proof of concept of a T-cell based vaccine targeting Sars-COV-2 Nucleocapsid antigen with the pro-immunogenic oligoDOM® technology	Osivax	SME	FR	F	VFI, UK/CEA, FR/
AVVAX-COVID- 19	Adjuvanted virosomal COVID-19vaccine preventing virus transmission and minimizing the risk of enhanced disease.	Mymetics SA	SME	СН	М	iBET, PT/IME, DE/HZI, DE/BPRC, NL
SysImmCoV2	Host signatures predicting SARS-CoV-2 antibody responses and their association with protection	ISGIobal	Research Institution	ES	F	iBET, PT/IME, DE/HZI, DE/Bioaster, FR, LU, NL/CEA, FR/UNISI, IT
Covivax	Identification of a SARS-CoV-2 vaccine effective in ferret infection model	Takis biotech	SME	т //	М	PHE, UK



TRANSVAC – Past, present (& future?)

TRANSVAC2

- 2017-2022
- 25 partners
- 9 EU MS
- H2020

Transition

- Continuation of certain services
- Organisation of events (workshops, meetings etc)
- Preparation and submission of follow-up grant

TRANSVAC1

- 2009-2013
- 14 partners / 5 interested parties
- 7 EU MS
- FP7


TRANSVAC-DS

- 2020-2022
- 26 partners
- 9 EU MS
- H2020

TRANSVAC

Sustainable & stable vaccine R&D infrastructure

- Implementation
- Operation



Concept development Design & Preparation Implemenation & Operation

FP7

Horizon 2020

Horizon Europe

Beyond Horizons



Horizon Europe – RIs and vaccines?

Pillar 1

Excellent Science

European Research Council

Marie Skłodowska-Curie Actions

Research Infrastructures

Pillar 2

Global Challenges and European Industrial Competitiveness

- Health
- · Culture, Creativity and **Inclusive Society**
- Civil Security for Society
 Digital, Industry and Space
 Climate, Energy and Mobility

 - · Food, Bioeconomy, Natural Resources, Agriculture and **Environment**

Joint Research Centre

Pillar 3

Innovative Europe

European Innovation Council

European innovation ecosystems

European Institute of Innovation and Technology


Widening Participation and Strengthening the European Research Area

Widening participation and spreading excellence

Reforming and Enhancing the European R&I system



Horizon Europe – RIs and vaccines?



Pillar 3
Innovative Europe

European Innovation Council

European innovation ecosystems

European Institute of Innovation and Technology


Widening Participation and Strengthening the European Research Area


Widening participation and spreading excellence

Reforming and Enhancing the European R&I system




RICH H Europe & RIs: Assembling the puzzle







RICH HEurope – Missions, Parternships etc.





Conclusions – RIs & H Europe

- Many -too many?- potential opportunities
- H Europe budget chops: too little funding for too many things?
- COVID *et al* have come to stay: shouldn't there be more money for health R&D?



Find out more at www.transvac.org

Contact us:

transvacinfo@euvaccine.eu

stefan.jungbluth@euvaccine.eu

Follow European Vaccine Initiative





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.